Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design (2011)
- Authors:
- USP affiliated author: SILVA, CARLOS HENRIQUE TOMICH DE PAULA DA - FCFRP
- School: FCFRP
- DOI: 10.1080/08927022.2011.589052
- Subjects: NEOPLASIAS; QUÍMICA FARMACÊUTICA; PLANEJAMENTO DE FÁRMACOS; MODELAGEM MOLECULAR; HOMOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Molecular Simulations
- ISSN: 0892-7022
- Volume/Número/Paginação/Ano: v. 37, n. 14, p. 1186-1206, 2011
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SEMIGHINI, Evandro P.; TAFT, Carlton A.; SILVA, Carlos Henrique Tomich de Paula da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design. Molecular Simulations, Essex, v. 37, n. 14, p. 1186-1206, 2011. Disponível em: < http://dx.doi.org/10.1080/08927022.2011.589052 > DOI: 10.1080/08927022.2011.589052. -
APA
Semighini, E. P., Taft, C. A., & Silva, C. H. T. de P. da. (2011). Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design. Molecular Simulations, 37( 14), 1186-1206. doi:10.1080/08927022.2011.589052 -
NLM
Semighini EP, Taft CA, Silva CHT de P da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design [Internet]. Molecular Simulations. 2011 ; 37( 14): 1186-1206.Available from: http://dx.doi.org/10.1080/08927022.2011.589052 -
Vancouver
Semighini EP, Taft CA, Silva CHT de P da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design [Internet]. Molecular Simulations. 2011 ; 37( 14): 1186-1206.Available from: http://dx.doi.org/10.1080/08927022.2011.589052 - RNA interference in drug discovery
- Planejamento racional de inibidores de enzimas-alvo aplicado a diferentes doenças: modelagem, síntese, bioquímica e QSAR
- Química computacional no planejamento de candidatos a quimioterápicos
- Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia
- Identification of novel chemical entities for Adenosine receptor type 2A using molecular modeling approaches
- Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms
- General aspects of lead finding and optimization in drug discovery
- Pharmacophore-based drug design of novel potential tau ligands for Alzheimer's disease treatment
- Molecular dynamics, density functional theory, pharmacophore modeling, molecular interaction fields and ADME/tox investigation of novel bioactive compounds interacting with CDK2 surfaces
- Dinâmica molecular: teoria e aplicações em planejamento de fármacos
Informações sobre o DOI: 10.1080/08927022.2011.589052 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
